Name
RF4-03: (T-DXd) vs (T-DM1) in patients with high-risk human epidermal growth factor receptor 2-positive (HER2+) primary (BC) with residual invasive disease after neoadjuvant therapy: Interim analysis of DESTINY-Breast05 - Commentary By: Sarah Sammons, MD
Date & Time
Wednesday, December 3, 2025
Speakers
Virtual Session Link
Total Minutes
04:59
OnDemand Video URL